GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. Their pioneering research is based on a strong heritage, stemming from in-house knowledge and their desire to strive for excellence. Their drug discovery efforts are based on selecting specific nuclear receptors as targets and utilizing rational drug design to optimize their drug candidates. This strong skill base associated to their scientific and clinical expertise, translational disease-driven approach and strong bioinformatics capabilities, have allowed us to build a solid scientific platform enabling us to discover and develop their drug candidates and diagnostic tools. Professor Bart Staels, a world-renowned expert in nuclear receptors, co-founded GENFIT and has played a key role in shaping their company’s expertise over the years. Today, he sits as chair of the Scientific Advisory Board, lending decades of experience and essential know-how, supporting their role as an innovative leader in the discovery of solutions for the metabolic field.

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Xuanzhu Biopharmaceutical Co., Ltd. engages in the research and development of chemical and biological drugs. Its products include small molecular chemical drugs, monoclonal antibodies, bispecific antibodies, and antibody conjugated drugs. The company was founded in 2002 and is headquartered in Shijiazhuang, China.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Eastern Biotech is a pharmaceutical product development and manufacturing company. The company develops treatments for diabetes and obesity through medical research.

Beijing Jingyi Taixiang Technology Development Co., Ltd., established on 2001-05-29, Business scope includes technology promotion,Technical Services;Technical testing;Technology Import and Export,Import and export,Agent import and export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Hisamitsu Pharmaceutical Co., Ltd, a subsidiary of Hisamitsu Pharmaceutical Co., Inc., is a Taiwanese company located in Taipei. The firm manufactures and markets pharmaceuticals.

MEDIOGEN is a life science and probiotics products company.

Ildong Pharmaceutical Co., Ltd. engages in the manufacture and sale of medicines, ingredients for medicines, health supplements and special nutritional products. Its products include vitamins, antibiotics, gastric ulcer medicine, peptic ulcerative agents, and diet pills. The company was founded on August 1, 2016 and is headquartered in Seoul, South Korea.

Shenzhen Turier Biotech Co. Ltd. is a Chinese company that develops pharmaceutical products.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Guangdong Zhongsheng Ruichuang Biotechnology Co. Ltd. is a Chinese company located in Shenzhen. The firm develops biotechnologies. It was founded in 2018 by Chao Feng Long.

Peking Union Medical College Hospital, also known as Beijing Xiehe Hospital (Chinese: 北京协和医院), is a renowned general hospital in Beijing, China. It was founded in 1921 by Rockefeller Foundation and is affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS). During the Cultural Revolution, it was renamed the "Anti-imperialist Hospital".

Shanghai Sine Pharmaceutical Co. Ltd., part of Shanghai Pharmaceuticals Holding Co., Ltd., is a company headquartered in Shanghai, China, that manufactures and distributes pharmaceutical products. On February 03, 2010 Shanghai Pharmaceuticals Holding Co., Ltd. acquired Shanghai Sine Pharmaceutical Co. Ltd. from Shanghai Pharmaceutical (Group) Co., Ltd. for $124.70 million.

Parnell Pharmaceuticals, Inc. is a private company headquartered in San Rafael, CA, that develops, manufactures and markets animal health products. It was founded in 1986 by Diana D. Parnell and Francis W. Parnell. Francis W. Parnell has been the CEO since the inception date.\nThe company says this about itself: Parnell Pharmaceuticals, Inc. is a closely held, private pharmaceutical company founded in 1986 and headquartered in San Rafael, California with an office in Dublin, Ireland. The company develops, manufactures, and markets prescription and OTC drug products that maintain and restore mucosal and skin integrity. The products are natural-based and patented for oral and nasal care, personal care, and anti-infective use. Parnell products are marketed and distributed in North America and Europe.

MYR GmbH engages in operating an biotechnology company. It focuses on the development and commercialization of therapeutics for the treatment of chronic hepatitis B (HBV) and D (HDV) infections. The company was founded by Joern Moeller and Alexander Alexandrov in 2010 and is headquartered in Bad Homburg, Germany.

Part of GSK Plc, GlaxoSmithKline Intellectual Property Development Ltd. is a British company located in Middlesex that functions as an investment holding company. It was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies (the \"Group\") and carrying out research and development activities.